Abstract
The increasing use of (±) 3,4-methylenedioxymethamphetamine (MDMA) in the setting of large dance parties (‘raves’) and clubs has been the source of some concern, because of potential acute adverse events, and because animal studies suggest that MDMA has the potential to damage brain serotonin (5-HT) neurons. However, it is not yet known whether MDMA, as used in the setting of dance parties, leads to plasma levels of MDMA that are associated with toxicity to 5-HT neurons in animals. The present study sought to address this question. Plasma MDMA concentrations, vital signs, and a variety of blood and urine measures were obtained prior to, and hours after, individuals attended a dance party. After the dance party, subjects were without clinical complaints, had measurable amounts of residual MDMA in plasma, and nearly half of the subjects also tested positive for methamphetamine, another amphetamine analog that has been shown to have 5-HT neurotoxic potential in animals. Plasma concentrations of MDMA did not correlate with self-reported use of ‘ecstasy’ and, in some subjects, overlapped with those that have been associated with 5-HT neurotoxicity in non-human primates. Additional subjects were likely to have had similar concentrations while at the dance party, when one considers the reported time of drug ingestion and the plasma half-life of MDMA in humans. Hematological and biochemical analyses were generally unremarkable. Moderate increases in blood pressure, heart rate and body temperature were observed in the subjects with the highest MDMA plasma concentrations. These findings are consistent with epidemiological findings that most people who use MDMA at dance parties do not develop serious clinical complications, and suggest that some of these individuals may be at risk for developing MDMA-induced toxicity to brain serotonin neurons.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Almond CS, Shin AY, Fortescue EB, Mannix RC, Wypij D, Binstadt BA et al (2005). Hyponatremia among runners in the Boston Marathon. N Engl J Med 352: 1550–1556.
Baselt RC (2002). Disposition of Toxic Drugs & Chemicals in Man, 6th edn. Chemical Toxicology Institute: London. pp 687–688.
Bowyer JF, Young JF, Slikker W, Itzak Y, Mayorga AJ, Newport GD et al (2003). Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or D-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24: 379–390.
Colado MI, Williams JL, Green AR (1995). The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115: 1281–1289.
Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002). The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97: 1531–1536.
Comer SD, Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW (2001). Effects of repeated oral methamphetamine administration in humans. Psychopharmacology 155: 397–404.
de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN et al (2000). Non-linear pharmacokinetics of MDMA (‘ecstasy’) in humans. Br J Clin Pharmacol 49: 104–109.
de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M et al (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137–144.
Gowing LR, Henry-Edwards SM, Irvine RJ, Ali RL (2002). The health effects of ecstasy: a literature review. Drug Alcohol Rev 21: 53–63.
Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’). Pharmacol Rev 55: 463–508.
Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW, Hanson GR (1996). Mechanisms for tolerance to methamphetamine effects. Neuropharmacology 35: 751–757.
Hegadoren KM, Baker GB, Bourin M (1999). 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23: 539–553.
Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996). Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20: 432–440.
Kalant H (2001). The pharmacology and toxicology of ‘ecstasy’ (MDMA) and related drugs. Can Med Assoc J 165: 917–928.
Kraemer T, Maurer HH (2002). Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 24: 277–289.
Lora-Tamayo C, Tena T, Rodriguez A, Moreno D, Sancho JR, Ensenat P et al (2004). The designer drug situation in Ibiza. Forensic Sci Int 140: 195–206.
Mechan A, Yuan J, Hatzidimitriou G, Irvine R, McCann U, Ricaurte G (2006). Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: Relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31: 339–350.
Odell M, Drummer OH (2001). The Forensic Pharmacology of Drugs of Abuse, 1st edn, Oxford University Press: Oxford.
Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN et al (1999). Immunomodulating properties of MDMA alone and in combination with alcohol: a pilot study. Life Sci 65: PL309–PL316.
Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN et al (2002). Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann NY Acad Sci 965: 421–433.
Pacifici R, Zuccaro P, Hernandez Lopez C, Pichini S, Di Carlo S, Farre M et al (2001). Acute effects of 3,4-methylenedioxymethamphetamine alone and in combination with ethanol on the immune system in humans. J Pharmacol Exp Ther 296: 207–215.
Parrott AC (2005). Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19: 71–83.
Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, Maurer HH (2003). Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J Anal Toxicol 27: 552–559.
Ricaurte GA, Yuan J, McCann UD (2000). 3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42: 5–10.
Samyn N, De Boeck G, Wood M, Lamers CT, De Waard D, Brookhuis KA et al (2002). Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Forensic Sci Int 128: 90–97.
Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH (2003). Review of deaths related to taking ecstasy, England and Wales, 1997–2000. BMJ 326: 80–81.
Schmidt CJ, Gehlert DR, Peat MA, Sonsalla PK, Hanson GR, Wamsley JK et al (1985). Studies on the mechanism of tolerance to methamphetamine. Brain Res 343: 305–313.
Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J (2004). Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a WWW study. Addict Behav 29: 743–752.
Segal DS, Kuczenski R, O’Neil ML, Melega WP, Cho AK (2003). Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28: 1730–1740.
Steele T, McCann U, Ricaurte G (1994). 3,4-Methylenedioxymethamphetamine (MDMA, ‘ecstasy’): pharmacology and toxicology in animals and humans. Br J Addict 89: 539–551.
Topp L, Hando J, Dillon P, Roche A, Solowij N (1999). Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105–115.
Acknowledgements
This study was partly supported by the National Health and Medical Research Council of Australia (RJI) and USPHS Grant DA10217 (UDM).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Irvine, R., Keane, M., Felgate, P. et al. Plasma Drug Concentrations and Physiological Measures in ‘Dance Party’ Participants. Neuropsychopharmacol 31, 424–430 (2006). https://doi.org/10.1038/sj.npp.1300896
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300896
Keywords
This article is cited by
-
Ecstasy: PMMA, MDMA en hooggedoseerde pillen
Verslaving (2015)
-
MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study
Psychopharmacology (2011)
-
Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats
Psychopharmacology (2011)
-
Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Molecular Neurobiology (2009)
-
MDMA Induces EPSP–Spike Potentiation in Rat Ventral Hippocampus In Vitro Via Serotonin and Noradrenaline Release and Coactivation of 5-HT4 and β1 Receptors
Neuropsychopharmacology (2008)
